Patents Assigned to Hoffmann-La Roche Inc.
-
Patent number: 11655243Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1-R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: GrantFiled: December 17, 2020Date of Patent: May 23, 2023Assignees: HOFFMANN-LA ROCHE INC., EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICHInventors: Simon M. Ametamey, Kenneth Atz, Luca Gobbi, Uwe Grether, Wolfgang Guba, Julian Kretz
-
Publication number: 20230149395Abstract: Provided herein are methods of treating Relapsing Multiple Sclerosis (RMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 1, 2021Publication date: May 18, 2023Applicants: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Hideki GARREN, Edmond Huatung TENG, Aurelien VIACCOZ, Hans-Christian VON BUEDINGEN
-
Publication number: 20230151424Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulatorType: ApplicationFiled: June 16, 2022Publication date: May 18, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Marie-Pierre Dube, Jean-Claude Tardif
-
Publication number: 20230154626Abstract: Systems and methods described herein improve outcomes of subjects with lymphoma. Subjects with lymphoma may be able to avoid conventional treatments that have a high probability of leading to an adverse effect in the subject. Systems and methods allow for a more accurate prediction of subjects who cannot tolerate a particular treatment. Methods may include accessing an input data set that includes multiple input data values pertaining to a particular subject with lymphoma. The method may further include inputting the input data set into a machine-learning model to generate a score corresponding to the degree to which the particular subject will tolerate a particular treatment. The method may include outputting a prediction of the tolerance of the particular subject to the particular treatment using the generated score.Type: ApplicationFiled: January 19, 2023Publication date: May 18, 2023Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.Inventors: Tina Geritz Nielsen, Joseph Nathaniel Paulson, Daniel Jay Schneider, Edward Jean Bataillard, Carl Wilson Harris, III, Carsten Henneges, Yoonha Choi
-
Publication number: 20230150995Abstract: The invention provides novel compounds having the general formula I wherein R and X are as defined herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: January 20, 2023Publication date: May 18, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Guido GALLEY, Patrick SCHNIDER
-
Publication number: 20230143310Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.Type: ApplicationFiled: June 30, 2022Publication date: May 11, 2023Applicant: Hoffmann-La Roche Inc.Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK
-
Publication number: 20230141600Abstract: The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein Rx and R3 to R5 are as described herein: or pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.Type: ApplicationFiled: December 6, 2022Publication date: May 11, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Zhanling CHENG, Christian KRAMER, Christian LERNER, Yongqiang LIU, Matthias NETTEKOVEN, Philippe PFLIEGER, Sébastien SCHMITT, Theodor STOLL, Jianhua WANG, Yongguang WANG, Song YANG, Chengang ZHOU
-
Publication number: 20230144399Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R11 are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 14, 2018Publication date: May 11, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Song FENG, Zongxing QIU, Guolong WU, Dongdong CHEN, Chao LI
-
Publication number: 20230141603Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds for treatment of CNS disorders.Type: ApplicationFiled: October 18, 2022Publication date: May 11, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Frédéric KNOFLACH, Andreas KOBLET, Eoin Cornelius O'CONNOR, Andres Miguel OLIVARES MORALES, Valerie RUNTZ-SCHMITT, Jaclyn WAMSTEEKER CUSULIN, Nicolas ZORN
-
Publication number: 20230141403Abstract: The invention provides novel imidazopyrazine derivatives having the general formula (I), or pharmaceutically acceptable salts thereof, wherein X, m, n, and R1 to R3 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.Type: ApplicationFiled: December 6, 2022Publication date: May 11, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Zhanling CHENG, Xingchun HAN, Christian KRAMER, Holger KUEHNE, Christian LERNER, Mingming LI, Matthias NETTEKOVEN, Theodor STOLL, Min WANG, Song YANG
-
Publication number: 20230142171Abstract: The invention provides novel heterocyclic compounds having the general formula (I) or (II), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.Type: ApplicationFiled: October 4, 2022Publication date: May 11, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Bjoern BARTELS, Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Roland HUMM, Andrés Miguel OLIVARES MORALES, Angélique PATINY-ADAM, Valerie RUNTZ-SCHMITT, Christian SCHNIDER
-
Publication number: 20230133845Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.Type: ApplicationFiled: July 14, 2022Publication date: May 4, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Mathis BRAENDLIN, Sandra Marie Joseph GRALL-ULSEMER, Xingchun HAN, Christian LERNER, Mingming LI, Yongqiang LIU, Sébastien SCHMITT, Jianhua WANG, Yongguang WANG, Min WANG, Song YANG, Chengang ZHOU
-
Publication number: 20230134606Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: June 30, 2022Publication date: May 4, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
-
Publication number: 20230136326Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.Type: ApplicationFiled: September 28, 2022Publication date: May 4, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Bjoern BARTELS, Giuseppe CECERE, Guido GALLEY, Luca GOBBI, Maria-Clemencia HERNANDEZ, Andreas KOBLET, Andrés Miguel OLIVARES MORALES, Angélique PATINY-ADAM, Valerie RUNTZ-SCHMITT
-
Publication number: 20230135093Abstract: The invention provides compounds having the general formula (I) or (II) wherein R1, R2, R3, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: November 11, 2022Publication date: May 4, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Giuseppe CECERE, Guillaume DÉCORET, Katrin GROEBKE ZBINDEN, Maria-Clemencia HERNANDEZ, Henner KNUST, Andreas KOBLET, Andres Miguel OLIVARES MORALES, Emmanuel PINARD, Valerie RUNTZ-SCHMITT
-
Patent number: 11639394Abstract: The invention relates to bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to epithelial cell adhesion molecule (EpCAM), and to methods of producing these molecules and to methods of using the same.Type: GrantFiled: September 25, 2019Date of Patent: May 2, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Sandra Grau-Richards, Christian Klein, Pablo Umaña, Maria Amann, Laurene Pousse
-
Publication number: 20230131782Abstract: Herein is reported a method for determining the epitope of an antibody specifically binding to a therapeutic antibody comprising the steps of a) incubating a sample, which comprises serum and the antibody specifically binding to a therapeutic antibody, separately with i) at least a Fab fragment of the therapeutic antibody, and ii) at least a Fab fragments of the therapeutic antibody in which the HVRs forming a paratope have been replaced with germline sequences, and detecting the binding or non-binding of the antibody specifically binding to a therapeutic antibody to the at least a Fab fragment in any of i) to ii), and b) determining the epitope of the antibody specifically binding to a therapeutic antibody to be in the at least one HVR that has been replaced in ii) if binding is detected in i) and non-binding is detected in ii).Type: ApplicationFiled: June 30, 2022Publication date: April 27, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Roland BECKMANN, Ekkehard MOESSNER, Kay-Gunnar STUBENRAUCH
-
Publication number: 20230129340Abstract: Herein are provided a method for producing a multispecific antibody comprising the steps of providing a mammalian cell expressing the antibody, transfecting said mammalian cell with an expression vector comprising an expression cassette encoding a polypeptide of the antibody that has a domain crossover, cultivating the transfected cell and recovering the antibody from the cell or the cultivation medium and thereby producing the multispecific antibody.Type: ApplicationFiled: May 25, 2022Publication date: April 27, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Stefan SEEBER, Ulrich GOEPFERT, Andrea OSTERLEHNER, Hubert KETTENBERGER, Wolfgang PAUL
-
Publication number: 20230123268Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3 and n are as defined herein, compositions including methods of making the compounds and using the compounds as ATX inhibitors.Type: ApplicationFiled: December 7, 2022Publication date: April 20, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Angélica BEURIER, Luke GREEN, Christian KRAMER, Dmitry MAZUNIN, Emmanuel PINARD, Hasane RATNI
-
Patent number: D984469Type: GrantFiled: March 17, 2022Date of Patent: April 25, 2023Assignee: Hoffmann-La Roche Inc.Inventor: Kevin Adam Stewart